Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: hypertrophic cardiomyopathy (HCM)

histopathologic image of tissue from a hypertrophied heart

Myocardium Histology Predicts Long-Term Outcomes of Obstructive Hypertrophic Cardiomyopathy

High composite score in myectomy specimens signals worse prognosis

Obstructive hypertrophic cardiomyopathy

REMS Update: Mavacamten Still Effective in Treating Real-World Patients With HCM

Few patients report left ventricular dysfunction or heart failure after one year

cardiac MRI showing obstructive hypertrophic cardiomyopathy

Final VALOR-HCM Report: At 128 Weeks, Mavacamten Sustains Gains in HCM Patients

Avoidance of septal reduction therapy continues while LVEF dysfunction remains infrequent

left ventricular apex in heart affected by hypertophic cardiomopathy

Registry Study Identifies Hallmarks of Apical Hypertrophic Cardiomyopathy

New risk score pools factors that may predict adverse outcomes in the uncommon phenotype

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

echocardiogram showing strain imaging assessment

Mavacamten’s Effects on Strain Imaging in Obstructive HCM: Insights From VALOR-HCM

Serial strain assessments show sustained favorable impacts on LV systolic function and LA function

hypertrophied human heart

A Transaortic Approach to Midventricular and Apical Septal Myectomy

Large single-center series demonstrates safety and efficacy for extending procedure

CQD-4040874-vigorousexercise-650×450
January 22, 2024/Pediatrics/Cardiology

Is Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy Less Risky Than Previously Thought?

JAMA study adds new data to decades-long guidance

HVI_Kelley_4277155_Patient Procedure Shoot- First in Human Trial
October 27, 2023/Genomic Medicine

Cleveland Clinic Treats First Patient With Investigational Gene Therapy for Hypertrophic Cardiomyopathy

One-time infusion of adenovirus-based therapy is designed to restore heart muscle function

23-HVI-4172009 CQD 650×450-2

Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

22-HVI-3509429_obstructive-hypertrophic-cardiomyopathy_650x450

Advances in Hypertrophic Cardiomyopathy Therapy: VALOR-HCM May Be Just the Beginning

An abundance of promising studies are on the horizon

BackPage 1 of 3Next

Advertisement

Ad